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Abstract
Oral mucositis is an important side effect of
hematopoietic stem cell transplantation
(HCST), mainly due to toxicity of conditioning
regimens. It produces significant pain and mor-
bidity. The present study reports a prospective,
randomized, non-blinded study testing the effi-
cacy of a new mouthwash, called Baxidil Onco®
(Sanitas Farmaceutici Srl, Tortona, Italy) in 60
hematologic patients undergoing HCST (28
autologous, 32 allogeneic). Baxidil Onco®, used
three times a day from Day -1 to Day +30, in
addition to standard prophylactic schedules,
was administered to 14 patients undergoing
autologous and 14 patients undergoing allo-
geneic HCST. The remaining 32 patients (14
autologous and 18 HCST) were treated only
with standard prophylactic schedules and
served as control. In our study, the overall inci-
dence of oral mucositis, measured according to
the World Health Organization 0-4 scale, was
50% in the Baxidl Onco® group versus 82% in
the control group (P=0.022). In addition, a sig-
nificant reduction in scale 2-4 oral mucositis
was observed in the Baxidil Onco® group (25%
vs 56.2%; P=0.0029). The results obtained indi-
cate that incidence, severity and duration of
oral mucositis induced by conditioning regi-
mens for HCST can be significantly reduced by
oral rinsing with Baxidil Onco®, in addition to
the standard prophylaxis scheme. Since
Camelia Sinensin extract, which is used to pro-
duce green tea, is the main agent in this mouth-
wash, we hypothesize that the anti-oxidative
properties of polyphenolic compounds of tea
might exert protective effects on oral mucosa.
Introduction
Oral mucositis (OM) is one of the most fre-
quent and important side effects of many anti-
cancer therapies and has a significant physical
and psychological impact for a large number of
patients treated for neoplasias.1-4 The most
important consequences of OM are pain, dys-
phagia, requirement of parenteral nutrition,
increased risk of mucosal and systemic infec-
tions, poor quality of life, delayed discharge
from hospital.
Polychemotherapy is associated with OM in
approximately 5-15% of hematologic patients
treated with standard doses.5 A higher inci-
dence can be expected when agents such as
thymidylate synthase inhibitors (methotrex-
ate), topoisomerase II inhibitors (etoposide,
irinotecan), pyrimidine analogs (cytarabine),
purine analogs (6-mercaptopurine and 6-
thioguanine), alkylating agents (busulfan,
melphalan and cyclophosphamide), and inter-
calating drugs (idarubicin, doxorubicin,
daunorubicin) are used at high doses.5
The frequency of OM further increases in
the setting of stem cell transplantation.5,6
Conditioning regimens used in autologous
peripheral blood hematopoietic stem cell
transplantation (HSCT) cause OM in approxi-
mately 35-75% of patients,7,8 while in the allo-
geneic HCST setting the incidence of OM
reaches 75-100%, depending on the type of dis-
ease, transplant procedure and conditioning
regimen.9-11 OM induced by chemo- and radio-
therapy seems to be caused by a combination
of several pathways, including direct DNA and
mucosal damage, increased production of
reactive oxygen species, increased production
of transcription factors, production of pro-
inflammatory cytokines. As a consequence,
loss of epithelial integrity, and increased apop-
tosis and necrosis of mucosal cells occur, fol-
lowed by various degrees of bleeding, ulcera-
tion, bacterial colonization, and increased risk
of systemic infection.9,12 For all of these rea-
sons, the clinical approach to OM should
include both prevention and treatment of man-
ifestations. Prevention may include various
measures, such as topical antimicrobials, bar-
rier protectants, ice, and adequate oral
hygiene.12 For treatment of OM, various agents
have been proposed and used, such as
cryotherapy,13 low-level laser therapy,14
chlorhexidine,15,16 a naturally occurring
antimicrobial agent,17 and measures aimed at
increasing epithelial cell regeneration and
attenuating pro-inflammatory cytokine produc-
tion.5,18 In the present paper, we present the
results of a randomized, non-blinded clinical
study carried out with the use of a new mouth-
wash, called Baxidil Onco® (Sanitas
Farmaceutici Srl, Tortona, Italy), in hematolog-
ic patients undergoing peripheral blood stem
cell (PBSC) transplantation. All patients were
treated with standard schedules for OM pre-
vention, while Baxidil Onco® was used as an
additive agent in a subgroup of patients after
randomization. 
Materials and MethodsPatients 
Sixty patients (males 39, females 21, age 21-
73 years) undergoing either autologous or allo-
geneic HCST were evaluated. They were man-
aged in a purpose built leukemia and bone
marrow transplantation unit. The patients
were suffering from: multiple myeloma (MM,
n=23), B-cell non-Hodgkin’s lymphomas (NHL,
n=14), acute myeloblastic leukemia (AML,
n=10), acute lymphoblastic leukemia (ALL,
n=7), chronic lymphocytic leukemia (CLL,
n=2), primary myelofibrosis (PMF, n=1),
myelodysplastic syndrome (MDS, n=1), parox-
ysmal nocturnal hemoglobinuria (PNH, n=1),
Hodgkin’s lymphoma (HL, n=1). Twenty-eight
patients were treated with transplantation of
autologous PBSC and the remaining 32
patients underwent transplantation of allo-
geneic PBSC (Table 1). The conditioning regi-
mens used to prepare patients for HCST, which
are routinely used in the HCST setting,19-27 are
shown in Table 2.  
All patients gave their informed consent to
undergo HCST, to be treated with growth fac-
tors and other drugs including antibiotics,
antifungals, antiviral agents, and to undergo
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OM prophylaxis with either standard sched-
ules or Baxidil Onco® mouthwash.Oral cavity examination 
Three experienced dental hygienists carried
out oral cavity examinations, with the support
of a mirror, a tongue retractor, and gauzes,
before starting conditioning (Day -1) and over
the 30-day period of the study. The visit includ-
ed examination and palpation of lips, frenum,
buccal mucosa, gingivae, hard palate, soft
palate, oropharynx, tonsils, tongue, floor of
the mouth. Finally, the oral hygiene index
(OHI-S) according to Greene and Vermilion
was calculated for each patient.28 All data were
registered on a dental chart.Oral mucositis measurement  
OM was measured according to the scoring
system published by the WHO.29 This scale
defines the state of the mucositis injuries
according to their severity (scale 0-4). This not
only values the presence of erythema and
ulceration, but also the patient’s capacity to
eat. In brief: grade 0, absence of symptoms;
grade 1, soreness and erythema, no further
symptoms; grade 2, ulcers present, but solid
diet possible; grade 3, only liquids can be swal-
lowed; grade 4, oral alimentation impossible. Standard prophylaxis and treatment for oral mucositis
According to internal guidelines developed
over time and approved by all physicians
involved in patient management, all patients
underwent the following prophylactic and ther-
apeutic procedures aimed at reducing the inci-
dence, duration and clinical impact of OM.
Initial management of OM (grade 0-1) was
with mouthwashes with 0.9% saline/sodium
bicarbonate solution, 0.12% chlorhexidine and
amphotericin B. 
A soft toothbrush could be used in grade 0-1
OM, but in OM of grade 2 or over oral hygiene
was maintained with a careful use of sponges
or soft gauzes. Patients were invited to wash
their mouth with 0.9% saline before topical
medication was applied to remove debris and
saliva. All patients received prophylaxis with
acyclovir 400 mg twice daily from Day -3 to 16
weeks, fluconazole 400 mg once daily,
ciprofloxacin 500 mg once daily, and cotrimox-
azole 960 mg twice daily until day of trans-
plant.Mouthwash administration 
Baxidil Onco® mouthwash was given to 28
patients (14 undergoing autologous and 14
allogeneic PBSC transplantation) after ran-
domization. Baxidil Onco® was used at 20 mL
four times daily, from Day -1 to Day +30.
Patients were asked to rinse their mouth for at
least one minute without swallowing. The
remaining 32 patients served as control.
General patient management 
All patients received granulocyte colony-
stimulating factor (rhG-CSF) 5 mg/kg/day until
white blood cell (WBC) count reached 0.5 x
109/L starting on Day 5 after PBSC infusion;
irradiated blood products were infused to
maintain hemoglobin and platelet levels above
8 g/dL and 10¥109/L, respectively. All patients
with an absolute neutrophil count of less than
0.5¥109/L (grade IV neutropenia) received
total parenteral nutrition (TPN); this was per-
formed only during the period of profound
reduction of neutrophils. Analgesic therapy
with morphine 20 mg daily in continuous
intravenous (i.v.) infusion was given to
patients with grade 3-4 OM. Statistical analysis 
The c2 test was used to compare results
obtained in the group of patients treated with
Baxidil Onco® versus the control group. 
Results
In the control group, 26 of 32 patients
(81.2%) experienced OM according to one of
the four grades of the WHO score system. There
was a statistically significant difference in the
overall incidence of OM in the group treated
with Baxidil Onco® (50%, 14 of 28 patients)
(P=0.022) (Table 3, Figure 1). When intermedi-
ate (grade 2) plus severe (grade 3-4) OM were
taken into account, a significant difference
(P=0.029) between controls and patients treat-
ed with Baxidil Onco® was still registered, with
18 of 32 patients (56.2%) versus 7 of 28 patients
(25%), respectively (Table 4). A lower incidence
of grade 3-4 OM was registered in the Baxidil
Onco® group (controls: 12 of 32, 37.5%; patients
treated with Baxidil Onco®: 5 of 28, 17.8%), but
a significant difference was not reached
(P=0.16) despite the clear trend towards a dif-
ferent incidence of ulcerative OM.
Article
Table 1. General characteristics of patients.
Disease Autologous HCST Allogeneic HCST
NHL 7 7
AML 0 10
ALL 0 7
MDS 0 1
HL 0 1
MM 21 2
B-CLL 0 2
PMF 0 1
PNH 0 1
NHL, B-cell non-Hodgkin’s lymphomas; AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome;
HL, Hodgkin’s lymphoma; MM, multiple myeloma; B-CLL, chronic lymphocytic leukemia; PMF, primary myelofibrosis; PNH, paroxysmal noctur-
nal hemoglobinuria. 
Table 2. Conditioning regimens used in autologous and allogeneic hematopoietic stem
cell transplantation.
Conditioning regimen Autologous n. Allogeneic n.
Melphalan-100 12 -
Melphalan-140 2 -
Melphalan-200 7 -
BEAM 5 3
FEAM 1 -
Melphalan/mitoxantrone 1 1
Busulfan/cyclophosphamide - 9
Fludarabine/TBI - 5
Cyclophosphamide/TBI/ATG - 3
Cyclophosphamide/thiotepa/TBI - 1
Thiotepa/fludarabine/melphalan - 2
Busulfan /cyclophosphamide/melphalan - 8
BEAM, association of carmustine, etoposide, cytosine arabinoside, melphalan; FEAM, association of fotemustine, etoposide, cytosine arabi-
noside, melphalan; TBI, total body irradiation; ATG, anti-thymocyte globulin.
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The higher incidence of OM was observed in
patients undergoing allogeneic HCST, both in
controls and in the group treated with Baxidil
Onco®. Mean duration of OM, when present,
was seven days for autologous HSCT and 13
days for allogeneic HCST, without any differ-
ence between controls and patients treated
with Baxidil Onco®. All patients experienced
grade IV neutropenia; this lasted in patients
undergoing allogeneic HCST. No difference
was found between the control group and the
group of patients treated with Baxidil Onco®
(Table 5). There was no difference between
controls and treated patients in terms of OHI-S
values as measured before PBSC infusion. In
addition, there was no correlation between
OHI-S values and severity of OM (Table 6).
According to our internal guidelines, all
patients were subjected to TPN during the
period of grade IV neutropenia, independently
of OM grading. The days of TPN were, there-
fore, different in the two groups of patients,
being longer in patients undergoing allogeneic
HCST. TPN was suspended once engraftment
was achieved, i.e. when absolute neutrophil
count reached 0.5¥109/L or over. A reduced
requirement of morphine was observed in
patients treated with Baxidil Onco® because of
the reduced number of patients who developed
grade 3-4 OM. The total requirement of mor-
phine was 1300 mg for patients treated with
Baxidil Onco® and 2880 mg in controls. No
adverse events were reported after use of
Baxidil Onco® mouthwash and all patients
considered it to have a good taste.
Discussion
This study provides evidence that Baxidil
Onco® mouthwash reduces both incidence and
severity of OM in hematologic patients under-
going either autologous or allogeneic HCST.
Although obtained in only a small series of
patients, our observation shows that Baxidil
Onco® mouthwash, used together with the
standard prophylactic measures adopted in our
transplant unit, was able to exert a protective
action, especially in patients treated with
autologous HCST who were conditioned with
melphalan alone or with the BEAM regimen.
The overall results showed that 50% of patients
did not experience OM.  Interestingly, Baxidil
Onco® exerts its action locally as a topical
agent. It is composed of Camelia Sinensis leaf
extract (which is used to produce green tea
and has anti-oxidative properties) and palmi-
toyil hydrolyzed wheat protein (a condensation
product of palmitic acid chloride and
hydrolyzed wheat protein, which might have
healing properties on skin and mucosa). Thus,
this mouthwash seems to be able to counteract
both increased production of reactive oxygen
species and the ulcerative damage that
induces and worsens OM. 
The most relevant activity of Baxidil Onco®
can be attributed to Camelia Sinensis extract.
The anti-oxidative properties of green tea are
well known. Most of the beneficial effects of
tea have been attributed to its polyphenolic
compounds, with particular evidence of three
catechins, such as epigallocatechin-3-gallate,
epigallocatechin and epicatchin-3-gallate.30
Catechins show direct antioxidative proper-
ties, leading to hydrogen atom transfer or sin-
gle electron transfer reactions, inhibition of
lipid peroxidation, and free radical scaveng-
ing.31,32 A particular protective effect is exerted
by epigallocatechin-3-gallate because of its
ability to decrease lipid peroxidation, oxidative
stress and the production of nitric oxide radi-
cals. Epigallocatechin-3-gallate also amelio-
rates the overproduction of pro-inflammatory
cytokines and mediators, and reduces the
activity of NF-KB and AP-1 and the subsequent
formation of peroxynitrite with nitric oxide
and reactive oxygen species.33 This antioxi-
dant effect of tea is supported by several clini-
cal studies and it is noteworthy that green tea
extracts retain the beneficial effects of green
Article
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Table 3. Cumulative results obtained in patients treated with Baxidil Onco® and com-
parison with controls.
Grade oral mucositis Controls Baxidil Onco®
n. % n. %
0 6 18.75 14 50
1 8 25 7 25
2 6 18.75 2 7
3 5 15.6 3 10.7
4 7 21.8 2 7
Table 4. Detailed results in autologous and allogeneic hematopoietic stem cell transplantation.
Grade oral mucositis Controls Baxidil Onco®
Total Autologous Allogeneic Total Autologous Allogeneic
0 6 4 2 14 9 5
1 8 4 4 7 5 2
2 6 5 1 2 0 2
3 5 0 5 3 0 3
4 7 1 6 2 0 2
Table 5.  Duration of grade IV neutropenia.
Patients Duration of grade IV neutropenia (days) P
Controls Baxidil Onco®
Allogeneic HCST 18.06±2.18 (n=18) 17.50±2.47 (n=14) NS
Autologous HCST 9.21±0.97 (n=14) 9.00±1.18 (n=14) NS
Figure 1. Percentage of distribution of oral
mucositis according to World Health
Organization grades in controls and in
patients treated with Baxidil Onco®.
No
n-c
om
me
rci
al 
us
 on
ly
[page 24] [Hematology Reports 2013; 5:e6]
and black tea.34,35 In addition, a beneficial
effect of Camelia Sinensis extracts on the
integrity of the oral mucosa after exposure to
cytotoxic drugs is supported by studies which
demonstrate that catechins extracted from
green tea are chemopreventive, natural heal-
ing, and anti-aging agents for human skin.36
Other medical mouthwashes, topical agents
(such as chlorhexidine, PVP-iodide or benzy-
damine) or cryotherapy have been evaluated in
medical studies carried out on small series of
patients. For example, Adamietz et al.37 evalu-
ated 20 patients undergoing radio-chemother-
apy and concluded that rinsing with povidone-
iodine was an easy, cheap and safe prophylac-
tic method and that it could be recommended
as a supportive treatment during antineoplas-
tic treatment of the head and neck region.
Pfeiffer et al.38 evaluated sucralfate (a well-
known gastric mucosal protective agent) in
OM prophylaxis in patients undergoing thera-
py with cisplatin and continuous infusion with
5-fluorouracil, and among 23 evaluable
patients found a significant reduction in an
objective score of edema, erythema, erosion
and ulcerations. However, 10 patients did not
complete the study since swishing the mouth-
wash around the mouth aggravated
chemotherapy-induced nausea. Salvador et
al.18 studied 23 patients undergoing transplan-
tation with autologous HCST and treated with
a 60-minute regimen of oral cryotherapy. They
found that the overall mean of oral mucositis
severity for the experimental arm was signifi-
cantly lower than that for the control group,
and that similar results could be observed in
terms of overall mean mucositis-related pain
score. They concluded that oral cryotherapy
plus an oral care protocol appeared to be bene-
ficial in preventing severe OM.
Some systematic reviews analyzed the
results of randomized studies carried out with
single agents that were considered potentially
useful in reducing incidence and/or severity of
OM in cancer patients. In one of these review
articles,39 four agents, each in single trials,
were found to exert a weak protective action
allopurinol, granulocyte macrophage-colony
stimulating factor (GM-CSF), immunoglobu-
lin, human placental extracts. The following
agents were not found to be effective: benzy-
damine, HCl, sucralfate, tetrachlorodecaoxide,
chlorhexidine.
Niscola et al.5 reviewed the results of clini-
cal trials involving various growth factors and
cytokines and reported no beneficial effects for
GM-CSF, transforming growth factor-ß3, whey-
derived growth factor extract, rhIL-11, epider-
mal growth factor.
There is consistent evidence for a protective
action of two agents that are given intra-
venously, such as repifermin (keratinocyte
growth factor-2) and palifermin (recombinant
human keratinocyte growth factor-1). 
Only one study evaluated the usefulness of
repifermin in patients undergoing autologous
hematopoietic stem cell transplantation.40
More information is available about palifer-
min. Following the first clinical study, reported
by Spielberger et al.41 carried out in patients
treated with chemotherapy, radiotherapy or
autologous HCST, a significant protective
action of palifermin has been confirmed, as
discussed by Blijlevens and Sonis.42 As far as
the allogeneic HCST setting is concerned, two
multicenter studies reported a reduced inci-
dence of OM (range 30-40%) in patients treat-
ed with palifermin, with a more significant
efficacy in the lower WHO OM grades.43,44
Amifostine is another systemic agent capa-
ble of reducing incidence and/or severity of OM
in hematologic patients undergoing HCST.
Both Capelli et al.45 and Thieblemont et al.46
reported a significant protective action of ami-
fostine in patients with multiple myeloma
receiving high-dose melphalan as a condition-
ing agent for autologous HCST, with a 50%
decrease in the occurrence of severe OM.
Conclusions
If we compare the results of our study with
these reports, which are very similar in terms
of both patients’ characteristics and number of
patients evaluated, we find that Baxidl Onco®
mouthwash exerted a protective action that
was comparable to that shown both by palifer-
min and by amifostine, without their possible
adverse effects. The results obtained in our
study indicate that oral rinsing with Baxidil
Onco® mouthwash in addition to the standard
prophylaxis can significantly reduce incidence,
severity and duration of OM. Compared to
other prophylactic agents, such as palifermin
and amifostine, we think that Baxidil Onco® is
cheaper, easier to use and capable of exerting
similar effects when used in hematologic
patients undergoing HCST. Further studies
involving a larger number of patients are need-
ed to validate the results obtained so far.
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